A 6-month Study to Evaluate Sulforaphane Effects in Schizophrenia Patients

Phase 2 Completed 125 enrolled Central South University

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of the study is to investigate whether adding sulforaphane will benefit the negative symptoms and cognitive function in individuals who have schizophrenia. This study will compare the sulforaphane with placebo. There is a thirty percent change (less than half) of receiving the placebo. The purpose of including placebo is to judge if the outcome is related to the study medication rather than other reasons.

Timeline

Start: 2020-08-31
Primary completion: 2022-08-12
Completion: 2022-08-12

Outcome

Met primary endpoint

paper Sulforaphane-treated patients showed a significantly greater decrease in PANSS negative symptom total score (P = .01) PMID 39832347 ↗

Publications

Huang J, Chen A, Jin H, Liu F, Hei G, Teng Z, Xiao J, Wu R, Zhao J, Davis JM, Shao P, Smith RC. Efficacy and Safety of Sulforaphane Added to Antipsychotics for the Treatment of Negative Symptoms of Schizophrenia: A Randomized Controlled Trial. J Clin Psychiatry. 2025 Jan 20;86(1):24m15272. doi: 10.4088/JCP.24m15272.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sulforaphane	Small molecule	1700 mg	—